Investigator-Initiated Studies

We’re committed to supporting investigator-initiated research that promotes the advancement of medical and scientific knowledge involving AbbVie’s products and therapeutic areas of interest.

Advancing science through investigator-led research

The research from Investigator-Initiated Studies may expand our understanding of our products and their potential applications. Plus, it may improve patient care and spark new ideas for further disease-related research. The AbbVie IIS Program provides an opportunity to academic and community-based physicians and researchers worldwide interested in conducting their own research to apply for research support.

Visit the AbbVie IIS submission portals to learn more or to apply:

IIS submission portal for legacy AbbVie associated products 

IIS submission portal for legacy Allergan associated products

How to apply

If you’re an investigator, you can initiate the application process by submitting a brief summary of the proposed research for AbbVie Products through either the IIS submission portal for legacy AbbVie associated products or through the IIS submission portal for legacy Allergan associated products

IIS applications are accepted on a rolling submission basis.

For assistance on how to submit an IIS application, please refer to the following training guides: 

Training guide for legacy AbbVie IIS submission portal 

Training guide for legacy Allergan IIS submission portal

After you apply

Following the review of the initial submission, you may be asked to submit a full protocol and final study budget for further evaluation. We hold protocol review meetings monthly. Submission of a proposal does not imply or guarantee approval. The committee evaluates proposals according to their scientific merit, alignment with our areas of research interest and available funding. Financial and/or product support is contingent upon full execution of the research agreement by both parties.

Therapeutic areas of interest

Please refer to the following documents to learn more about our 2021 IIS strategic priorities:

Therapeutic areas of interest for legacy AbbVie associated products

Therapeutic areas of interest for legacy Allergan associated products